Department of Ophthalmology, University of Brescia, Brescia, Italy.
Jpn J Ophthalmol. 2012 Nov;56(6):608-12. doi: 10.1007/s10384-012-0162-3. Epub 2012 Aug 23.
To report the effectiveness and safety of intravitreal bevacizumab injection (IVB) compared with low-fluence photodynamic therapy (L-PDT) in eyes with chronic central serous chorioretinopathy (CSC).
This was a prospective comparative interventional study of 22 patients affected by chronic CSC. Patients were randomly assigned to group 1 (12 patients treated with 1.25 mg IVB) and group 2 (10 patients treated with L-PDT). In group 2, PDT with verteporfin was delivered at low fluence (300 mW/cm(2) for 83 s, 25 J/cm(2)). Follow-up visits were scheduled at 1, 3, 6, and 9 months.
The improvement in visual acuity was greater in group 1 than in group 2, although the difference was not statistically significant (P = 0.59). The mean change in central point thickness over 9 months from baseline was 127 μm (SD 36) in group 1 and 114 μm (SD 42) in group 2. After the first injection, retreatments were given if recurrence was noted, with an average of 3.0 ± 1 injections in group 1 and 1.6 ± 0.6 treatments with L-PDT in group 2. The difference between retreatment in the 2 groups was not statistically significant (P = 0.45).
Based on the results obtained after 9 months of follow-up, our study provides evidence that IVB may be a treatment option for chronic CSC.
报告玻璃体内注射贝伐单抗（IVB）与低强度光动力疗法（L-PDT）治疗慢性中心性浆液性脉络膜视网膜病变（CSC）的疗效和安全性。
这是一项前瞻性比较干预研究，纳入 22 例慢性 CSC 患者。患者随机分为 1 组（12 例，给予 1.25mg IVB）和 2 组（10 例，给予 L-PDT）。在 2 组中，维替泊芬 PDT 采用低强度（300mW/cm2 照射 83s，25J/cm2）。随访时间为 1、3、6 和 9 个月。
1 组视力改善优于 2 组，但差异无统计学意义（P=0.59）。9 个月时中央点厚度的平均变化值为 1 组 127μm（SD 36），2 组 114μm（SD 42）。在第 1 次注射后，如果发现复发，将进行再次治疗，1 组平均需要 3.0±1 次注射，2 组需要 L-PDT 治疗 1.6±0.6 次。2 组间的再治疗差异无统计学意义（P=0.45）。
根据 9 个月的随访结果，本研究表明 IVB 可能是慢性 CSC 的一种治疗选择。
